Cargando…
Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
BACKGROUND: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). MATERIALS/METHODS: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data an...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540455/ https://www.ncbi.nlm.nih.gov/pubmed/37770836 http://dx.doi.org/10.1186/s12879-023-08596-z |
_version_ | 1785113723322499072 |
---|---|
author | Sipahi, Oguz Resat Akyol, Deniz Ormen, Bahar Cicek-Senturk, Gonul Mermer, Sinan Onal, Ugur Amer, Fatma Saed, Maysaa Abdallah Ozdemir, Kevser Tukenmez-Tigen, Elif Oztoprak, Nefise Altin, Ummugulsum Kurtaran, Behice Popescu, Corneliu Petru Sakci, Mustafa Suntur, Bedia Mutay Gautam, Vikas Sharma, Megha Kaya, Safak Akcil, Eren Fatma Kaya, Selcuk Turunc, Tuba Ergen, Pınar Kandemir, Ozlem Cesur, Salih Bardak-Ozcem, Selin Ozgiray, Erkin Yurtseven, Taskın Erdem, Huseyin Aytac Sipahi, Hilal Arda, Bilgin Pullukcu, Hüsnü Tasbakan, Meltem Yamazhan, Tansu Aydemir, Sohret Ulusoy, Sercan |
author_facet | Sipahi, Oguz Resat Akyol, Deniz Ormen, Bahar Cicek-Senturk, Gonul Mermer, Sinan Onal, Ugur Amer, Fatma Saed, Maysaa Abdallah Ozdemir, Kevser Tukenmez-Tigen, Elif Oztoprak, Nefise Altin, Ummugulsum Kurtaran, Behice Popescu, Corneliu Petru Sakci, Mustafa Suntur, Bedia Mutay Gautam, Vikas Sharma, Megha Kaya, Safak Akcil, Eren Fatma Kaya, Selcuk Turunc, Tuba Ergen, Pınar Kandemir, Ozlem Cesur, Salih Bardak-Ozcem, Selin Ozgiray, Erkin Yurtseven, Taskın Erdem, Huseyin Aytac Sipahi, Hilal Arda, Bilgin Pullukcu, Hüsnü Tasbakan, Meltem Yamazhan, Tansu Aydemir, Sohret Ulusoy, Sercan |
author_sort | Sipahi, Oguz Resat |
collection | PubMed |
description | BACKGROUND: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). MATERIALS/METHODS: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018. RESULTS: Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3–5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34). CONCLUSIONS: Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci. |
format | Online Article Text |
id | pubmed-10540455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105404552023-09-30 Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study Sipahi, Oguz Resat Akyol, Deniz Ormen, Bahar Cicek-Senturk, Gonul Mermer, Sinan Onal, Ugur Amer, Fatma Saed, Maysaa Abdallah Ozdemir, Kevser Tukenmez-Tigen, Elif Oztoprak, Nefise Altin, Ummugulsum Kurtaran, Behice Popescu, Corneliu Petru Sakci, Mustafa Suntur, Bedia Mutay Gautam, Vikas Sharma, Megha Kaya, Safak Akcil, Eren Fatma Kaya, Selcuk Turunc, Tuba Ergen, Pınar Kandemir, Ozlem Cesur, Salih Bardak-Ozcem, Selin Ozgiray, Erkin Yurtseven, Taskın Erdem, Huseyin Aytac Sipahi, Hilal Arda, Bilgin Pullukcu, Hüsnü Tasbakan, Meltem Yamazhan, Tansu Aydemir, Sohret Ulusoy, Sercan BMC Infect Dis Research BACKGROUND: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). MATERIALS/METHODS: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018. RESULTS: Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3–5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34). CONCLUSIONS: Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci. BioMed Central 2023-09-28 /pmc/articles/PMC10540455/ /pubmed/37770836 http://dx.doi.org/10.1186/s12879-023-08596-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Sipahi, Oguz Resat Akyol, Deniz Ormen, Bahar Cicek-Senturk, Gonul Mermer, Sinan Onal, Ugur Amer, Fatma Saed, Maysaa Abdallah Ozdemir, Kevser Tukenmez-Tigen, Elif Oztoprak, Nefise Altin, Ummugulsum Kurtaran, Behice Popescu, Corneliu Petru Sakci, Mustafa Suntur, Bedia Mutay Gautam, Vikas Sharma, Megha Kaya, Safak Akcil, Eren Fatma Kaya, Selcuk Turunc, Tuba Ergen, Pınar Kandemir, Ozlem Cesur, Salih Bardak-Ozcem, Selin Ozgiray, Erkin Yurtseven, Taskın Erdem, Huseyin Aytac Sipahi, Hilal Arda, Bilgin Pullukcu, Hüsnü Tasbakan, Meltem Yamazhan, Tansu Aydemir, Sohret Ulusoy, Sercan Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study |
title | Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study |
title_full | Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study |
title_fullStr | Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study |
title_full_unstemmed | Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study |
title_short | Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study |
title_sort | empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter ephesus study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540455/ https://www.ncbi.nlm.nih.gov/pubmed/37770836 http://dx.doi.org/10.1186/s12879-023-08596-z |
work_keys_str_mv | AT sipahioguzresat empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT akyoldeniz empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT ormenbahar empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT ciceksenturkgonul empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT mermersinan empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT onalugur empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT amerfatma empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT saedmaysaaabdallah empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT ozdemirkevser empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT tukenmeztigenelif empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT oztopraknefise empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT altinummugulsum empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT kurtaranbehice empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT popescucorneliupetru empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT sakcimustafa empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT sunturbediamutay empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT gautamvikas empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT sharmamegha empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT kayasafak empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT akcilerenfatma empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT kayaselcuk empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT turunctuba empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT ergenpınar empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT kandemirozlem empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT cesursalih empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT bardakozcemselin empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT ozgirayerkin empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT yurtseventaskın empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT erdemhuseyinaytac empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT sipahihilal empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT ardabilgin empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT pullukcuhusnu empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT tasbakanmeltem empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT yamazhantansu empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT aydemirsohret empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy AT ulusoysercan empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy |